Merck/Bayer’s Vericiguat Outcomes Data Less Impressive On Fuller Disclosure
Efficacy seen in reducing hospitalization in high-risk heart failure patients, but not in reducing the risk of cardiovascular death. Analysts say this portends a more niche opportunity for vericiguat.
You may also be interested in...
The Phase III VICTORIA study evaluating the safety of the sGC stimulator met its primary endpoint.
In addition to small molecules, stem cell therapies promise to help rejuvenate the chronic heart failure pipeline, but high prices and invasive procedures may limit their use to end-stage patients, and skepticism about efficacy persists.
Merck sells consumer care business, but also buys into Bayer’s franchise of sGC modulators.